Eli Lilly's Foundayo Poised to Disrupt Oral GLP-1 Market, Challenging Wegovy's Dominance

by : Robert Kiyosaki
Eli Lilly's recent FDA approval of Foundayo marks a pivotal moment in the weight loss medication sector, introducing a formidable challenger to an already competitive market. This oral GLP-1 treatment is set to redefine patient options and investor expectations, signaling a new era of innovation and competition.

Foundayo vs. Wegovy: The Battle for the Oral GLP-1 Crown

Eli Lilly's Foundayo Secures Key FDA Approval

In a significant development this month, Eli Lilly and Company (LLY) successfully obtained U.S. Food and Drug Administration (FDA) approval for its new once-daily oral obesity medication, orforglipron, marketed under the brand name Foundayo. This approval positions Foundayo as only the second oral GLP-1 treatment available, entering a rapidly expanding and highly anticipated market.

The Rise of Oral GLP-1 Medications: A New Era for Weight Management

Foundayo's market entry follows closely on the heels of Novo Nordisk A/S's (NVO) launch of an oral version of its popular weight-loss drug, Wegovy, in January. The introduction of these oral treatments represents a major shift from traditional injectable GLP-1 agonists, offering patients a more convenient and potentially more accessible option for managing obesity.

Revenue Projections: Foundayo Aims to Challenge Wegovy's Early Lead

Initial financial forecasts indicate that Foundayo is projected to generate approximately $1.6 billion in revenue by 2026. This figure stands in contrast to Wegovy's anticipated $11.4 billion for the same year. However, as market competition intensifies, Wegovy's projected revenue is expected to slightly decrease from roughly $12.4 billion in 2025. This suggests that Foundayo is poised to capture a significant share of the market, gradually narrowing the gap with its established competitor.

Ares Capital: Strong Performance Despite SaaS Loan Concerns
by : Fareed Zakaria
Ares Capital: Strong Performance Despite SaaS Loan Concerns
Ares Capital (ARCC) faces market skepticism due to private credit concerns, particularly around SaaS loans. However, ARCC maintains a solid 10% dividend yield, fully supported by net investment income, and boasts a high-quality loan portfolio. Q1'26 saw continued portfolio growth of 9% year-over-year, with a low non-accrual ratio of 1.2%, highlighting diligent underwriting practices. Despite the broader market's anxieties regarding SaaS debt, ARCC's financial health and balance sheet strength remain robust, leading to a 'Hold' recommendation for income-focused investors.
learn more
Columbia Disciplined Value Fund Outperforms Benchmark in Q1 2026
by : Mariana Mazzucato
Columbia Disciplined Value Fund Outperforms Benchmark in Q1 2026
The Columbia Disciplined Value Fund's Institutional Class shares delivered a 2.27% return in the first quarter of 2026, surpassing the Russell 1000 Value Index's 2.10%. This outperformance was primarily driven by strong stock selection in the energy, healthcare, and materials sectors, despite a broader market loss for U.S. equities due to private credit disruptions and AI concerns. The energy sector, in particular, benefited from rising crude oil prices and investor shifts towards companies with substantial physical assets.
learn more
Calamos Global Convertible Fund: Q1 2026 Performance Analysis
by : David Rubenstein
Calamos Global Convertible Fund: Q1 2026 Performance Analysis
The Calamos Global Convertible Fund (CXGCX) mirrored broader market trends in Q1 2026, ending the quarter with a modest 0.50% return. This period saw substantial global convertible issuance, totaling $53.3 billion, highlighting investor interest in this asset class. Notably, Lumentum Holdings Inc. experienced significant gains due to its strategic position in the AI and cloud data center expansion. The portfolio maintains a cautious stance on Europe, reflecting ongoing macro-economic challenges and regulatory hurdles that impact company growth.
learn more
Nexxen International: Navigating Programmatic Shifts in AdTech
by : Michele Ferrero
Nexxen, an AdTech company, faces challenges despite its low valuation and share repurchase program. The company is transitioning from traditional non-programmatic revenue to a programmatic approach, but flat FY25 revenue, declining CTV, and reduced profitability in Q4 raise concerns. Future growth hinges on the accelerated expansion of its programmatic core to counteract shrinking non-programmatic segments and achieve overall revenue growth.
Navigating Economic Crosscurrents: The Federal Reserve's Policy Dilemma
by : Strive Masiyiwa
The Federal Reserve faces a complex challenge as energy-driven inflation and decelerating growth converge. This article explores how supply shocks, particularly rising energy prices stemming from geopolitical tensions, complicate monetary policy decisions. Drawing on analysis from AIER's Sound Money Project, it examines the role of monetary policy rules, including the Taylor Rule and Nominal Gross Domestic Product (NGDP)-based frameworks, in guiding the Fed's approach to interest rates amidst these economic crosscurrents.
Austrian Nuns' Unexpected Journey to Rome and Vatican Audience
by : Mona Chalabi
Three elderly Austrian nuns, known for their unconventional escape from a care home to return to their former convent, have made their first visit to Rome. Sisters Rita, Bernadette, and Regina, all in their eighties, attended a general audience with Pope Leo XIV at St. Peter's Square. Their journey comes amid an ongoing dispute with their local provost regarding their living arrangements and vows of obedience, with the Vatican reportedly ruling in their favor to remain at the convent. The nuns have also gained an unexpected social media following, further highlighting their story.
Revolutionizing Tuberculosis Diagnostics: A New Era of Swift and Accurate Detection
by : Anderson Cooper
A groundbreaking tuberculosis test, the MiniDock MTB, has emerged as a beacon of hope in the global fight against this deadly infectious disease. Developed by Chinese company Pluslife, this innovative diagnostic tool offers a rapid, accurate, and cost-effective alternative to traditional phlegm-based tests. By utilizing tongue swabs and advanced machine scanning for TB DNA, it promises to significantly improve accessibility to testing, especially for vulnerable populations, and facilitate earlier treatment, thereby curbing transmission rates worldwide.